NASDAQ:CMPX
Compass Therapeutics, Inc. Stock News
$1.60
+0 (+0%)
At Close: May 20, 2024
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
08:00am, Tuesday, 14'th May 2024
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
08:00am, Monday, 13'th May 2024
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
08:00am, Friday, 12'th Apr 2024
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
08:00am, Wednesday, 10'th Apr 2024
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
3 Penny Stocks With the Power to 10X Your $1K Investment
04:00pm, Sunday, 24'th Mar 2024
Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
09:00am, Thursday, 21'st Mar 2024
Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line da
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
08:00am, Thursday, 29'th Feb 2024
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 08'th Feb 2024
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Therapeutics Provides Corporate Update
08:00am, Friday, 05'th Jan 2024
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Tuesday, 14'th Nov 2023
The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07:30am, Thursday, 09'th Nov 2023
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics to Participate in Upcoming Investor Events
08:00am, Wednesday, 30'th Aug 2023
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Thursday, 03'rd Aug 2023
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
08:00am, Tuesday, 22'nd Nov 2022
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, toda
